Indication intelligence, analysis and sector perception

Vericel (VCEL) positive top-line results from P2b ixCELL-DCM Ixmyelocel-T clinical trial

March 10, 2016 9:46am

This program has “lingered” for so long, I am surprised it has raised its “head”! Jump in the “que” with the comparables who also are advancing this indication – its crowded.

Still very much a positive and a share crowd pleaser however, the costs of advancing this trial will be “burdensome” with their cash position; better to seek a partner.

VCEL announced positive top-line results from its P2b ixCELL-DCM clinical trial of Ixmyelocel-T in patients with heart failure due to ischemic dilated cardiomyopathy.

Full data to be presented at American College of Cardiology 65th Annual Scientific Session & Expo on April 4 Statement

The Bottom Line: The “experimental” heart drug – don’t they mean “therapy” met the main goal of reducing death, hospitalizations and emergency visits in patients in a mid-stage study. Dilated cardiomyopathy is a progressive heart disease and a leading cause of heart failure.

VCEL should focus on their revenue directed "acquired" programs from Sanofi as the therapeutic trial continuation will drain the cash "pool". In the first 15 minutes of the open. the price is already slipping from the opening (high) range of $4.30.

VCEL closed at $2.12 and was UP +$2.06 on 2.796 M share volume following a pre-market indication of $1.92 or +90.57% to $4.04.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.